Last edition
News about "CK0801 Phase 2 clinical trial"
Cellenkos Inc. Wins US FDA Clearance for Phase 2 Trial of CK0801 in Aplastic Anemia
Cellenkos Inc. receives US Food and Drug Administration (FDA) clearance to initiate a Phase 2 multicentre trial of CK0801, evaluating safety and efficacy of cord blood-derived Tregs in transfusion-dependent aplastic anemia patients.
CK0801 Phase 2 Clinical Trial | 27/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members